Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Stacy

Showing results (61-70 of 69) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 69 results.
CNS Spectrums|December 28, 2018
Guidance for switching from off-label antipsychotics to pimavanserin for Parkinson's disease psychosis: an expert consensusKevin J Black, Henry Nasrallah, Stuart Isaacson, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|February 3, 2007
Diagnostic criteria for psychosis in Parkinson's disease: report of an NINDS, NIMH work groupBernard Ravina, Karen Marder, Hubert H Fernandez, et al.
Neuron|December 13, 2016
Functional Genomic Analyses of Mendelian and Sporadic Disease Identify Impaired eIF2α Signaling as a Generalizable Mechanism for DystoniaJoseph E Rittiner, Zachary F Caffall, Ricardo Hernández-Martinez, et al.
Annals of Neurology|June 11, 2015
Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: A double-blind, randomized, controlled trialC Warren Olanow, Raymond T Bartus, Tiffany L Baumann, et al.
Annals of Neurology|January 24, 2006
Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson diseaseAnthony E Lang, Steven Gill, Nik K Patel, et al.
The Lancet. Neurology|October 26, 2010
Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trialWilliam J Marks, Raymond T Bartus, Joao Siffert, et al.
Clinical and Translational Science|July 18, 2015
CTSA Consortium Consensus Scientific Review Committee (SRC) Working Group Report on the SRC ProcessesHarry P Selker, John B Buse, Robert M Califf, et al.
American Journal of Human Genetics|March 29, 2002
PARK3 influences age at onset in Parkinson disease: a genome scan in the GenePD studyAnita L DeStefano, Mark F Lew, Lawrence I Golbe, et al.
Archives of Neurology|July 21, 2004
Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trialRobert G Holloway, Ira Shoulson, Stanley Fahn, et al.
Pageof 7

Showing results (61-70 of 69) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 69 results.
CNS Spectrums|December 28, 2018
Guidance for switching from off-label antipsychotics to pimavanserin for Parkinson's disease psychosis: an expert consensusKevin J Black, Henry Nasrallah, Stuart Isaacson, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|February 3, 2007
Diagnostic criteria for psychosis in Parkinson's disease: report of an NINDS, NIMH work groupBernard Ravina, Karen Marder, Hubert H Fernandez, et al.
Neuron|December 13, 2016
Functional Genomic Analyses of Mendelian and Sporadic Disease Identify Impaired eIF2α Signaling as a Generalizable Mechanism for DystoniaJoseph E Rittiner, Zachary F Caffall, Ricardo Hernández-Martinez, et al.
Annals of Neurology|June 11, 2015
Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: A double-blind, randomized, controlled trialC Warren Olanow, Raymond T Bartus, Tiffany L Baumann, et al.
Annals of Neurology|January 24, 2006
Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson diseaseAnthony E Lang, Steven Gill, Nik K Patel, et al.
The Lancet. Neurology|October 26, 2010
Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trialWilliam J Marks, Raymond T Bartus, Joao Siffert, et al.
Clinical and Translational Science|July 18, 2015
CTSA Consortium Consensus Scientific Review Committee (SRC) Working Group Report on the SRC ProcessesHarry P Selker, John B Buse, Robert M Califf, et al.
American Journal of Human Genetics|March 29, 2002
PARK3 influences age at onset in Parkinson disease: a genome scan in the GenePD studyAnita L DeStefano, Mark F Lew, Lawrence I Golbe, et al.
Archives of Neurology|July 21, 2004
Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trialRobert G Holloway, Ira Shoulson, Stanley Fahn, et al.
Pageof 7